NEW YORK, Dec. 18 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc., , a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, announced that, effective today, it has begun trading its Common Stock on the New York Stock Exchange (the "NYSE") under ticker symbol "AOB." Accordingly, the Company's common stock will no longer trade on the American Stock Exchange and the NYSE Arca.
Tony Liu, Chairman and CEO of AOB commented, "We are pleased to commence trading on the New York Stock Exchange and believe our move to the NYSE further advances our commitment to enhancing shareholder value. We are very proud to be the first China-based pharmaceutical and nutraceutical company to list on the NYSE and are honored to be joining a group of other distinguished companies on this premier stock exchange."
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. (AOB) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
American Oriental Bioengineering Inc.CONTACT: Ashley M. Ammon & Bill Zima, Integrated Corporate Relations,Inc., +1-203-682-8200, for American Oriental Bioengineering Inc.
Web site: http://www.bioaobo.com/
